Form 8-K · Current Report · Filed 2024-11-21
ResMed Inc. Announces Annual Meeting Voting Results
On November 20, 2024, ResMed Inc. held its annual meeting of stockholders where shareholders elected eleven directors to the board, ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025, and approved the compensation of named executive officers on an advisory basis. The election of directors saw high approval rates, with minimal against or abstain votes. The ratification of KPMG LLP and the say-on-pay vote also received significant support from shareholders.
- Filer
- ResMed Inc. RMD · NYSE
- Filed
- Accession
- 0001193125-24-263501
- CIK
- 0000943819
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$241.55
Next session
+0.9%
Since filing
-12.7%
Latest close
$210.98
What happened, not what will happen — closing prices around the filing date.
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Never miss another RMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.